Furthermore, in SNU719 xenograft models, ATF4 silencing partially reversed pyrotinib’s therapeutic efficacy (Fig. 3G), manifesting as attenuated tumor growth suppression (reduced volume and weight) (Fig. 3H, I) and elevation of Ki-67 proliferation indices (Fig. 3J). The gene discussed is ATF4; the disease is neoplasm.